How have BPMUF shares performed in 2024?

Basilea Pharmaceutica's stock was trading at $41.00 on January 1st, 2024. Since then, BPMUF stock has increased by 8.4% and is now trading at $44.45. View the best growth stocks for 2024 here .

How do I buy shares of Basilea Pharmaceutica?

Shares of BPMUF stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here .

Does Basilea Pharmaceutica have any subsidiaries?

The following companies are subsidiares of Basilea Pharmaceutica: Conec UK Limited. Read More

OTCMKTS:BPMUF

Basilea Pharmaceutica (BPMUF) Stock Price, News & Analysis

→ A.I. “Perfect Storm” Could Send THESE Stocks Sky High (From InvestorPlace) (Ad)

Free BPMUF Stock Alerts

$44.45

0.00 (0.00%)

(As of 04/15/2024 ET)

Compare

Today's Range: $44.45
▼
$44.45
50-Day Range: $38.60
▼
$44.45
52-Week Range: $38.60
▼
$44.45

Volume: N/A
Average Volume: 100 shs
Market Capitalization: $526.73 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: N/A

Stock Analysis Chart Headlines Short Interest

Get Basilea Pharmaceutica alerts:

Ad InvestorPlace

A.I. “Perfect Storm” Could Send THESE Stocks Sky High

A little-known investment analyst whose performance beat out 15,000+ other experts in 2020 has identified an opportunity in the A.I. space. He's calling it A.I.'s perfect storm.

>>Check out what this A.I. Perfect Storm is<<

About Basilea Pharmaceutica Stock (OTCMKTS:BPMUF)

Basilea Pharmaceutica AG, a commercial-stage biopharmaceutical company, focuses on the development of products that address the medical needs in the therapeutic areas of oncology and anti-infectives. The company offers Cresemba, an intravenous and antifungal drug for the treatment of invasive aspergillosis and mucormycosis in the United States, and the European Union. It also offers medicine drug for invasive fungal infections. In addition, the company provides Zevtera, an antibiotic for the treatment of community and hospital-acquired pneumonia, as well as offers treatment of acute bacterial skin and skin structure infections, and Staphylococcus aureus bacteremia. Further, it offers Fosmanogepix, an antifungal drug for the treatment of Candidemia which in Phase II clinical trials. Basilea Pharmaceutica AG was founded in 2000 and is headquartered in Allschwil, Switzerland.

BPMUF Stock Price History

30 days | 90 days | 365 days | Advanced Chart

BPMUF Stock News Headlines

April 9, 2024 | finance.yahoo.com

Basilea awarded CARB-X grant to develop recently acquired novel class of antibiotics

April 8, 2024 | americanbankingnews.com

FY2024 EPS Estimates for Basilea Pharmaceutica AG (OTCMKTS:BPMUF) Boosted by HC Wainwright

April 16, 2024 | InvestorPlace (Ad)

A.I. “Perfect Storm” Could Send THESE Stocks Sky High

A little-known investment analyst whose performance beat out 15,000+ other experts in 2020 has identified an opportunity in the A.I. space. He's calling it A.I.'s perfect storm.

April 4, 2024 | msn.com

UPDATE 2-US FDA approves Basilea Pharmaceutica's antibiotic

April 4, 2024 | msn.com

European stocks rise ahead of inflation data; Basilea shines

April 4, 2024 | finance.yahoo.com

Basilea announces US FDA approval of antibiotic ZEVTERA® (ceftobiprole medocaril) for three indications

April 3, 2024 | reuters.com

US FDA approves Basilea Pharmaceutica's antibiotic

March 11, 2024 | finance.yahoo.com

Continued strong Cresemba® (isavuconazole) sales performance in Asia Pacific and China triggers milestone payment to Basilea

April 16, 2024 | InvestorPlace (Ad)

A.I. “Perfect Storm” Could Send THESE Stocks Sky High

A little-known investment analyst whose performance beat out 15,000+ other experts in 2020 has identified an opportunity in the A.I. space. He's calling it A.I.'s perfect storm.

February 21, 2024 | investing.com

Basilea Pharmaceutica AG (BSLN)

February 13, 2024 | finance.yahoo.com

Basilea reports strong 2023 full-year results with profitability significantly above guidance, whilst substantially expanding the R&D portfolio

January 19, 2024 | finance.yahoo.com

Cresemba® sales in Latin America trigger first sales milestone payment to Basilea

January 15, 2024 | markets.businessinsider.com

Basilea To Buy Preclinical Antibiotics Program From Spexis

January 15, 2024 | finance.yahoo.com

Basilea announces acquisition of preclinical antibiotics program from Spexis

January 5, 2024 | finance.yahoo.com

Basilea provides portfolio status update

December 20, 2023 | markets.businessinsider.com

Basilea Pharmaceutica Agrees With Athyrium On Early Repayment Of Senior Secured Loan

December 20, 2023 | finance.yahoo.com

Basilea announces accelerated loan repayment

December 11, 2023 | finance.yahoo.com

Basilea announces that FDA approves expanded use of antifungal Cresemba® (isavuconazole) in the United States in children with invasive aspergillosis and invasive mucormycosis

December 4, 2023 | finance.yahoo.com

Basilea Pharmaceutica AG's (VTX:BSLN) top owners are individual investors with 58% stake, while 39% is held by institutions

November 20, 2023 | finance.yahoo.com

Continued strong Cresemba® (isavuconazole) sales performance in Asia Pacific and China triggers third sales milestone payment for the region from Pfizer this year

November 13, 2023 | msn.com

Pfizer unit in pact with Swiss biotech Basilea to sell rights to antifungal

November 13, 2023 | finance.yahoo.com

Basilea announces acquisition of fosmanogepix, a phase-3-ready broad-spectrum antifungal

October 31, 2023 | finance.yahoo.com

Basilea announces exclusive license and option agreement for potential first-in-class clinical-stage antibacterial agent

October 19, 2023 | finance.yahoo.com

Basilea announces acquisition of novel clinical-stage antifungal for treatment of Aspergillus mold infections

October 17, 2023 | finance.yahoo.com

Basilea reports new data for ceftobiprole (Zevtera®) presented at US IDWeek Congress 2023

October 2, 2023 | finance.yahoo.com

Basilea announces FDA acceptance of New Drug Application for antibiotic ceftobiprole

September 28, 2023 | finance.yahoo.com

Basilea announces New England Journal of Medicine publication of phase 3 data on ceftobiprole for the treatment of Staphylococcus aureus bacteremia

See More Headlines

Receive BPMUF Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Basilea Pharmaceutica and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Today: 4/16/2024
Fiscal Year End: 12/31/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: OTCMKTS
Sector: Medical
Industry: Pharmaceutical preparations
Sub-Industry: N/A
Current Symbol: OTCMKTS:BPMUF
CUSIP: N/A
CIK: N/A
Web: www.basilea.com
Phone: (161) 606-1111
Fax: 41-61-606-1112
Employees: 147
Year Founded: N/A

Profitability

EPS (Most Recent Fiscal Year): N/A
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: N/A
Net Margins: N/A
Pretax Margin: N/A
Return on Equity: N/A
Return on Assets: N/A

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 3.20
Quick Ratio: 2.64

Sales & Book Value

Annual Sales: $175.50 million
Price / Sales: 3.00
Cash Flow: $1.13 per share
Price / Cash Flow: 39.34
Book Value: ($0.94) per share
Price / Book: -47.29

Miscellaneous

Outstanding Shares: 11,850,000
Free Float: N/A
Market Cap: $526.73 million
Optionable: Not Optionable
Beta: 0.65

Social Links

The 10 Best AI Stocks to Own in 2024

Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.

Get This Free Report

Key Executives

Mr. David Veitch (Age 59)
Chief Executive Officer
Comp: $1.26M
Mr. Adesh Kaul (Age 50)
Chief Financial Officer
Dr. Gerrit Hauck Ph.D. (Age 60)
Chief Technology Officer
Dr. Laurenz Kellenberger Ph.D. (Age 57)
Chief Scientific Officer
Dr. Marc Engelhardt M.D. (Age 60)
Chief Medical Officer
Dr. Peer Nils Schroder
Head of Corporate Communications & Investor Relations
Mr. Damian Heller (Age 58)
General Counsel & Corporate Secretary
Mr. Andreas Kumin
Head of Corporate Development
Ms. Ursula Eberhardt (Age 62)
Head of Global Human Resources
Mr. Mark Jones (Age 56)
Head of Project Management & Preclinical Development

Key Competitors

View All Competitors

BPMUF Stock Analysis - Frequently Asked Questions

How have BPMUF shares performed in 2024?: Basilea Pharmaceutica's stock was trading at $41.00 on January 1st, 2024. Since then, BPMUF stock has increased by 8.4% and is now trading at $44.45.
View the best growth stocks for 2024 here.
How do I buy shares of Basilea Pharmaceutica?: Shares of BPMUF stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.
Does Basilea Pharmaceutica have any subsidiaries?: The following companies are subsidiares of Basilea Pharmaceutica: Conec UK Limited.
Read More

This page (OTCMKTS:BPMUF) was last updated on 4/16/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

Basilea Pharmaceutica (BPMUF) Stock Price, News & Analysis

About Basilea Pharmaceutica Stock (OTCMKTS:BPMUF)

BPMUF Stock Price History

BPMUF Stock News Headlines

Company Calendar

Industry, Sector and Symbol

Profitability

Debt

Sales & Book Value

Miscellaneous

Social Links

Key Executives

Key Competitors

BPMUF Stock Analysis - Frequently Asked Questions

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info